Regulation of bile acid and cholesterol metabolism by PPARs

PPAR Research

Volumn , Issue , 2009, Pages

  Chiang, John Y L ^a   Li, Tiangang ^a  

^a NORTHEAST OHIO MEDICAL UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABC TRANSPORTER A1; ATORVASTATIN; BEZAFIBRATE; BILE ACID; CHOLESTANETRIOL 26 MONOOXYGENASE; CHOLESTEROL; CHOLESTEROL 7ALPHA MONOOXYGENASE; CLOFIBRATE; FENOFIBRATE; FIBRIC ACID DERIVATIVE; GEMFIBROZIL; GW 610742; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PIRINIXIC ACID; ROSIGLITAZONE; STEROL REGULATORY ELEMENT BINDING PROTEIN 2; TORCETRAPIB; UNCLASSIFIED DRUG; URSODEOXYCHOLIC ACID;

ATHEROSCLEROSIS; BILE ACID SYNTHESIS; CARDIOVASCULAR RISK; CHOLESTEROL METABOLISM; CHOLESTEROL STONE; CHOLESTEROL TRANSPORT; CLINICAL TRIAL; DYSLIPIDEMIA; HEART DISEASE; HUMAN; HYPERLIPIDEMIA; INTESTINE; INTESTINE ABSORPTION; LIVER; METABOLIC SYNDROME X; NONHUMAN; REVIEW;

EID: 68949122515     PISSN: 16874757     EISSN: 16874765     Source Type: Journal    
DOI: 10.1155/2009/501739     Document Type: Review

References (149)

1. Evans R. M., Barish G. D., Wang Y.-X., PPARs and the complex journey to obesity Nature Medicine 2004 10 4 355 361
2. Issemann I., Green S., Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators Nature 1990 347 6294 645 650
3. Dreyer C., Krey G., Keller H., Givel F., Helftenbein G., Wahli W., Control of the peroxisomal -oxidation pathway by a novel family of nuclear hormone receptors Cell 1992 68 5 879 887
4. Kliewer S. A., Forman B. M., Blumberg B., Differential expression and activation of a family of murine peroxisome proliferator-activated receptors Proceedings of the National Academy of Sciences of the United States of America 1994 91 15 7355 7359
5. Wang Y.-X., Lee C.-H., Tiep S., Peroxisome-proliferator-activated receptor activates fat metabolism to prevent obesity Cell 2003 113 2 159 170
6. Barish G. D., Narkar V. A., Evans R. M., PPAR:a dagger in the heart of the metabolic syndrome Journal of Clinical Investigation 2006 116 3 590 597
7. Russell D. W., Setchell K. D. R., Bile acid biosynthesis Biochemistry 1992 31 20 4737 4749
8. Chiang J. Y., Regulation of bile acid synthesis Frontiers in Bioscience 1998 3 D176 D193
9. Chiang J. Y., Bile acid regulation of gene expression: roles of nuclear hormone receptors Endocrine Reviews 2002 23 4 443 463
10. Myant N. B., Mitropoulos K. A., Cholesterol 7 alpha-hydroxylase Journal of Lipid Research 1977 18 2 135 153
11. Bjorkhem I., Mechanism of degradation of the steroid side chain in the formation of bile acids Journal of Lipid Research 1992 33 4 455 471
12. Axelson M., Sjovall J., Potential bile acid precursors in plasmapossible indicators of biosynthetic pathways to cholic and chenodeoxycholic acids in man Journal of Steroid Biochemistry 1990 36 6 631 640
13. Axelson M., Mork B., Sjovall J., Occurrence of 3 -hydroxy-5-cholestenoic acid, 3,7 -dihydroxy-5-cholestenoic acid, and 7 -hydroxy-3-oxo-4-cholestenoic acid as normal constituents in human blood Journal of Lipid Research 1988 29 5 629 641
14. Pikuleva I. A., Babiker A., Waterman M. R., Bjrkhem I., Activities of recombinant human cytochrome P450c27 (CYP27) which produce intermediates of alternative bile acid biosynthetic pathways Journal of Biological Chemistry 1998 273 29 18153 18160
15. Trauner M., Boyer J. L., Bile salt transporters: molecular characterization, function, and regulation Physiological Reviews 2003 83 2 633 671
16. Boyer J. L., New concepts of mechanisms of hepatocyte bile formation Physiological Reviews 1980 60 2 303 326
17. Meier P. J., Molecular mechanisms of hepatic bile salt transport from sinusoidal blood into bile American Journal of Physiology 1995 269 6 G801 G812
18. Kullak-Ublick G. A., Stieger B., Hagenbuch B., Meier P. J., Hepatic transport of bile salts Seminars in Liver Disease 2000 20 3 273 292
19. Meier P. J., Stieger B., Bile salt transporters Annual Review of Physiology 2002 64 635 661
20. Meier P. J., Eckhardt U., Schroeder A., Hagenbuch B., Stieger B., Substrate specificity of sinusoidal bile acid and organic anion uptake systems in rat and human liver Hepatology 1997 26 6 1667 1677
21. Jacquemin E., Hagenbuch B., Stieger B., Wolkoff A. W., Meier P. J., Expression cloning of a rat liver Na+-independent organic anion transporter Proceedings of the National Academy of Sciences of the United States of America 1994 91 1 133 137
22. No B., Hagenbuch B., Stieger B., Meier P. J., Isolation of a multispecific organic anion and cardiac glycoside transporter from rat brain Proceedings of the National Academy of Sciences of the United States of America 1997 94 19 10346 10350
23. Cattori V., Hagenbuch B., Hagenbuch N., Identification of organic anion transporting polypeptide 4 (Oatp4) as a major full-length isoform of the liver-specific transporter-1 (rlst-1) in rat liver FEBS Letters 2000 474 2-3 242 245
24. Abe T., Kakyo M., Tokui T., Identification of a novel gene family encoding human liver-specific organic anion transporter LST-1 Journal of Biological Chemistry 1999 274 24 17159 17163
25. Childs S., Yeh R. L., Georges E., Ling V., Identification of a sister gene to P-glycoprotein Cancer Research 1995 55 10 2029 2034
26. Strautnieks S. S., Kagalwalla A. F., Tanner M. S., Identification of a locus for progressive familial intrahepatic cholestasis PFIC2 on chromosome 2q24 American Journal of Human Genetics 1997 61 3 630 633
27. Oude Elferink R. P. J., Groen A. K., Mechanisms of biliary lipid secretion and their role in lipid homeostasis Seminars in Liver Disease 2000 20 3 293 305
28. Smit J. J. M., Schinkel A. H., Elferink R. P., Homozygous disruption of the murine mdr2 P-glycoprotein gene leads to a complete absence of phospholipid from bile and to liver disease Cell 1993 75 3 451 462
29. Langheim S., Yu L., von Bergmann K., ABCG5 and ABCG8 require MDR2 for secretion of cholesterol into bile Journal of Lipid Research 2005 46 8 1732 1738
30. Yu L., Gupta S., Xu F., Expression of ABCG5 and ABCG8 is required for regulation of biliary cholesterol secretion Journal of Biological Chemistry 2005 280 10 8742 8747 (Pubitemid 40409561)
31. Shneider B. L., Dawson P. A., Christie D.-M., Hardikar W., Wong M. H., Suchy F. J., Cloning and molecular characterization of the ontogeny of a rat ileal sodium-dependent bile acid transporter Journal of Clinical Investigation 1995 95 2 745 754
32. Oelkers P., Kirby L. C., Heubi J. E., Dawson P. A., Primary bile acid malabsorption caused by mutations in the ileal sodium-dependent bile acid transporter gene (SLC10A2) Journal of Clinical Investigation 1997 99 8 1880 1887
33. Gong Y.-Z., Everett E. T., Schwartz D. A., Norris J. S., Wilson F. A., Molecular cloning, tissue distribution, and expression of a 14-kDa bile acid-binding protein from rat ileal cytosol Proceedings of the National Academy of Sciences of the United States of America 1994 91 11 4741 4745
34. Dawson P. A., Hubbert M., Haywood J., The heteromeric organic solute transporter -, Ost -Ost, is an ileal basolateral bile acid transporter Journal of Biological Chemistry 2005 280 8 6960 6968
35. Ballatori N., Fang F., Christian W. V., Li N., Hammond C. L., Ost -Ost is required for bile acid and conjugated steroid disposition in the intestine, kidney, and liver American Journal of Physiology 2008 295 1 G179 G186
36. Grundy S. M., Ahrens E. H. Jr., Salen G., Mechanisms of action of clofibrate on cholesterol metabolism in patients with hyperlipidemia Journal of Lipid Research 1972 13 4 531 551
37. Kesaniemi Y. A., Grundy S. M., Influence of gemfibrozil and clofibrate on metabolism of cholesterol and plasma triglycerides in man Journal of the American Medical Association 1984 251 17 2241 2246
38. Leiss O., von Bergmann K., Gnasso A., Augustin J., Effect of gemfibrozil on biliary metabolism in normolipemic subjects Metabolismml: Clinical and Experimental 1985 34 1 74 82
39. Leiss O., Meyer-Krahmer K., von Bergmann K., Biliary lipid secretion in patients with heterozygous familial hypercholesterolemia and combined hyperlipidemia. Influence of bezafibrate and fenofibrate Journal of Lipid Research 1986 27 7 713 723
40. Stahlberg D., Reihnr E., Rudling M., Berglund L., Einarsson K., Angelin B. O., Influence of bezafibrate on hepatic cholesterol metabolism in gallstone patients: reduced activity of cholesterol 7 -hydroxylase Hepatology 1995 21 4 1025 1030
41. Bertolotti M., Concari M., Loria P., Effects of different phenotypes of hyperlipoproteinemia and of treatment with fibric acid derivatives on the rates of cholesterol 7 -hydroxylation in humans Arteriosclerosis, Thrombosis, and Vascular Biology 1995 15 8 1064 1069
42. Pullinger C. R., Eng C., Salen G., Human cholesterol 7 -hydroxylase (CYP7A1) deficiency has a hypercholesterolemic phenotype Journal of Clinical Investigation 2002 110 1 109 117
43. Marrapodi M., Chiang J. Y. L., Peroxisome proliferator-activated receptor (PPAR ) and agonist inhibit cholesterol 7 -hydroxylase gene (CYP7A1) transcription Journal of Lipid Research 2000 41 4 514 520
44. Patel D. D., Knight B. L., Soutar A. K., Gibbons G. F., Wade D. P., The effect of peroxisome-proliferator-activated receptor- on the activity of the cholesterol 7 -hydroxylase gene Biochemical Journal 2000 351 3 747 753
45. Post S. M., Duez H., Gervois P. P., Staels B., Kuipers F., Princen H. M. G., Fibrates suppress bile acid synthesis via peroxisome proliferator-activated receptor- -mediated downregulation of cholesterol 7 -hydroxylase and sterol 27-hydroxylase expression Arteriosclerosis, Thrombosis, and Vascular Biology 2001 21 11 1840 1845
46. Diczfalusy U., Lund E., Ltjohann D., Bjrkhem I., Novel pathways for elimination of cholesterol by extrahepatic formation of side-chain oxidized oxysterols Scandinavian Journal of Clinical and Laboratory Investigation, Supplement 1996 56 226 9 17
47. Bjorkhem I., Diczfalusy U., Lutjohann D., Removal of cholesterol from extrahepatic sources by oxidative mechanisms Current Opinion in Lipidology 1999 10 2 161 165
48. Szanto A., Benko S., Szatmari I., Transcriptional regulation of human CYP27 integrates retinoid, peroxisome proliferator-activated receptor, and liver X receptor signaling in macrophages Molecular and Cellular Biology 2004 24 18 8154 8166
49. Quinn C. M., Jessup W., Wong J., Kritharides L., Brown A. J., Expression and regulation of sterol 27-hydroxylase (CYP27A1) in human macrophages: a role for RXR and PPAR ligands Biochemical Journal 2005 385 3 823 830
50. Hofmann A. F., Bile acids as drugs: principles, mechanisms of action and formulations Italian Journal of Gastroenterology 1995 27 2 106 113
51. Ishida H., Kuruta Y., Gotoh O., Yamashita C., Yoshida Y., Noshiro M., Structure, evolution, and liver-specific expression of sterol 12 -hydroxylase P450 (CYP8B) Journal of Biochemistry 1999 126 1 19 25
52. Hunt M. C., Yang Y.-Z., Eggertsen G., The peroxisome proliferator- activated receptor (PPAR ) regulates bile acid biosynthesis Journal of Biological Chemistry 2000 275 37 28947 28953
53. Kok T., Bloks V. W., Wolters H., Peroxisome proliferator-activated receptor (PPAR )-mediated regulation of multidrug resistance 2 (Mdr2) expression and function in mice Biochemical Journal 2003 369 3 539 547
54. Cheng X., Klaassen C. D., Critical role of PPAR- in perfluorooctanoic acid- and perfluorodecanoic acid-induced downregulation of oatp uptake transporters in mouse livers Toxicological Sciences 2008 106 1 37 45
55. Jung D., Fried M., Kullak-Ublick G. A., Human apical sodium-dependent bile salt transporter gene (SLC10A2) is regulated by the peroxisome proliferator-activated receptor α Journal of Biological Chemistry 2002 277 34 30559 30566
56. Landrier J. F., Thomas C., Grober J., The gene encoding the human ileal bile acid-binding protein (I-BABP) is regulated by peroxisome proliferator-activated receptors Biochimica et Biophysica Acta 2005 1735 1 41 49
57. Moschetta A., Bookout A. L., Mangelsdorf D. J., Prevention of cholesterol gallstone disease by FXR agonists in a mouse model Nature Medicine 2004 10 12 1352 1358
58. Zandbergen F., Plutzky J., PPAR in atherosclerosis and inflammation Biochimica et Biophysica Acta 2007 1771 8 972 982
59. Shepherd J., Cobbe S. M., Ford I., Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia The New England Journal of Medicine 1995 333 20 1301 1307
60. Downs J. R., Clearfield M., Weis S., Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS Journal of the American Medical Association 1998 279 20 1615 1622
61. Sever P. S., Dahlf B., Poulter N. R., Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes TrialLipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial The Lancet 2003 361 9364 1149 1158
62. Baigent C., Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins The Lancet 2005 366 9493 1267 1278
63. Shah P. K., Low-density lipoprotein lowering and atherosclerosis progression: does more mean less? Circulation 2002 106 16 2039 2040
64. Genest J. Jr., McNamara J. R., Ordovas J. M., Lipoprotein cholesterol, apolipoprotein A-I and B and lipoprotein (a) abnormality in men with premature coronary heart disease Journal of the American College of Cardiology 1992 19 792 802
65. Gordon T., Castelli W. P., Hjortland M. C., Kannel W. B., Dawber T. R., High density lipoprotein as a protective factor against coronary heart disease. The Framingham study American Journal of Medicine 1977 62 5 707 714
66. Yaari S., Goldbourt U., Even-Zohar S., Neufeld H. N., Associations of serum high density lipoprotein and total cholesterol with total, cardiovascular, and cancer mortality in a 7-year prospective study of 10 000 men The Lancet 1981 1 8228 1011 1015
67. Desprs J.-P., Increasing high-density lipoprotein cholesterol: an update on fenofibrate American Journal of Cardiology 2001 88 12A 30N 36N
68. Birjmohun R. S., Hutten B. A., Kastelein J. J. P., Stroes E. S. G., Efficacy and safety of high-density lipoprotein cholesterol-increasing compounds: a meta-analysis of randomized controlled trials Journal of the American College of Cardiology 2005 45 2 185 197
69. Lewis G. F., Determinants of plasma HDL concentrations and reverse cholesterol transport Current Opinion in Cardiology 2006 21 4 345 352
70. Badimon J. J., Badimon L., Fuster V., Regression of atherosclerotic lesions by high density lipoprotein plasma fraction in the cholesterol-fed rabbit Journal of Clinical Investigation 1990 85 4 1234 1241
71. Duverger N., Kruth H., Emmanuel F., Inhibition of atherosclerosis development in cholesterol-fed human apolipoprotein A-I-transgenic rabbits Circulation 1996 94 4 713 717
72. Dimayuga P., Zhu J., Oguchi S., Reconstituted HDL containing human apolipoprotein A-1 reduces VCAM-1 expression and neointima formation following periadventitial cuff-induced carotid injury in apoE null mice Biochemical and Biophysical Research Communications 1999 264 2 465 468
73. Berthou L., Duverger N., Emmanuel F., Opposite regulation of human versus mouse apolipoprotein A-I by fibrates in human apolipoprotein A-I transgenic mice Journal of Clinical Investigation 1996 97 11 2408 2416
74. Vu-Dac N., Chopin-Delannoy S., Gervois P., The nuclear receptors peroxisome proliferator-activated receptor and rev-erb mediate the species-specific regulation of apolipoprotein A-I expression by fibrates Journal of Biological Chemistry 1998 273 40 25713 25720
75. Staels B., van Tol A., Andreu T., Auwerx J., Fibrates influence the expression of genes involved in lipoprotein metabolism in a tissue-selective manner in the rat Arteriosclerosis and Thrombosis 1992 12 3 286 294
76. Peters J. M., Hennuyer N., Staels B., Alterations in lipoprotein metabolism in peroxisome proliferator-activated receptor -deficient mice Journal of Biological Chemistry 1997 272 43 27307 27312
77. Brunham L. R., Singaraja R. R., Hayden M. R., Variations on a gene: rare and common variants in ABCA1 and their impact on HDL cholesterol levels and atherosclerosis Annual Review of Nutrition 2006 26 105 129
78. McNeish J., Aiello R. J., Guyot D., High density lipoprotein deficiency and foam cell accumulation in mice with targeted disruption of ATp-binding cassette transporter-1 Proceedings of the National Academy of Sciences of the United States of America 2000 97 8 4245 4250
79. Chinetti G., Lestavel S., Bocher V., PPAR- and PPAR- activators induce cholesterol removal from human macrophage foam cells through stimulation of the ABCA1 pathway Nature Medicine 2001 7 1 53 58
80. Akiyama T. E., Sakai S., Lambert G., Conditional disruption of the peroxisome proliferator-activated receptor gene in mice results in lowered expression of ABCA1, ABCG1, and apoE in macrophages and reduced cholesterol efflux Molecular and Cellular Biology 2002 22 8 2607 2619
81. Venkateswaran A., Laffitte B. A., Joseph S. B., Control of cellular cholesterol efflux by the nuclear oxysterol receptor LXR Proceedings of the National Academy of Sciences of the United States of America 2000 97 22 12097 12102
82. Chawla A., Boisvert W. A., Lee C.-H., A PPAR -LXR-ABCA1 pathway in macrophages is involved in cholesterol efflux and atherogenesis Molecular Cell 2001 7 1 161 171
83. Laffitte B. A., Joseph S. B., Walczak R., Autoregulation of the human liver X receptor promoter Molecular and Cellular Biology 2001 21 22 7558 7568
84. Brunham L. R., Kruit J. K., Iqbal J., Intestinal ABCA1 directly contributes to HDL biogenesis in vivo Journal of Clinical Investigation 2006 116 4 1052 1062
85. Timmins J. M., Lee J.-Y., Boudyguina E., Targeted inactivation of hepatic Abca1 causes profound hypoalphalipoproteinemia and kidney hypercatabolism of apoA-I Journal of Clinical Investigation 2005 115 5 1333 1342
86. Knight B. L., Patel D. D., Humphreys S. M., Wiggins D., Gibbons G. F., Inhibition of cholesterol absorption associated with a PPAR -dependent increase in ABC binding cassette transporter A1 in mice Journal of Lipid Research 2003 44 11 2049 2058
87. Inazu A., Brown M. L., Hesler C. B., Increased high-density lipoprotein levels caused by a common cholesteryl-ester transfer protein gene mutation The New England Journal of Medicine 1990 323 18 1234 1238
88. van der Hoogt C. C., De Haan W., Westerterp M., Fenofibrate increases HDL-cholesterol by reducing cholesteryl ester transfer protein expression Journal of Lipid Research 2007 48 8 1763 1771
89. Kastelein J. J. P., van Leuven S. I., Burgess L., Effect of torcetrapib on carotid atherosclerosis in familial hypercholesterolemia The New England Journal of Medicine 2007 356 16 1620 1630
90. Nissen S. E., Tardif J.-C., Nicholls S. J., Effect of torcetrapib on the progression of coronary atherosclerosis The New England Journal of Medicine 2007 356 13 1304 1316
91. Athyros V. G., Papageorgiou A. A., Athyrou V. V., Demitriadis D. S., Pehlivanidis A. N., Kontopoulos A. G., Atorvastatin versus four statin-fibrate combinations in patients with familial combined hyperlipidaemia Journal of Cardiovascular Risk 2002 9 1 33 39
92. Ellen R. L. B., McPherson R., Long-term efficacy and safety of fenofibrate and a statin in the treatment of combined hyperlipidemia American Journal of Cardiology 1998 81 4A 60B 65B
93. Vega G. L., Ma P. T. S., Cater N. B., Effects of adding fenofibrate (200mg/day) to simvastatin (10mg/day) in patients with combined hyperlipidemia and metabolic syndrome American Journal of Cardiology 2003 91 8 956 960
94. Knight B. L., Hebbach A., Hauton D., A role for PPAR in the control of SREBP activity and lipid synthesis in the liver Biochemical Journal 2005 389 2 413 421
95. Berndt J., Gaumert R., Still J., Mode of action of the lipid-lowering agents, elofibrate and BM 15075, on cholesterol biosynthesis in rat liver Atherosclerosis 1978 30 2 147 152
96. Klopotek A., Hirche F., Eder K., PPAR gamma ligand troglitazone lowers cholesterol synthesis in HepG2 and Caco-2 cells via a reduced concentration of nuclear SREBP-2 Experimental Biology and Medicine 2006 231 8 1365 1372
97. Brown M. S., Goldstein J. L., A proteolytic pathway that controls the cholesterol content of membranes, cells, and blood Proceedings of the National Academy of Sciences of the United States of America 1999 96 20 11041 11048
98. Yang T., Espenshade P. J., Wright M. E., Crucial step in cholesterol homeostasis: sterols promote binding of SCAP to INSIG-1, a membrane protein that facilitates retention of SREBPs in ER Cell 2002 110 4 489 500
99. Yabe D., Brown M. S., Goldstein J. L., Insig-2, a second endoplasmic reticulum protein that binds SCAP and blocks export of sterol regulatory element-binding proteins Proceedings of the National Academy of Sciences of the United States of America 2002 99 20 12753 12758
100. Kast-Woelbern H. R., Dana S. L., Cesario R. M., Rosiglitazone induction of Insig-1 in white adipose tissue reveals a novel interplay of peroxisome proliferator-activated receptor and sterol regulatory element-binding protein in the regulation of adipogenesis Journal of Biological Chemistry 2004 279 23 23908 23915
101. Knig B., Koch A., Spielmann J., Hilgenfeld C., Stangl G. I., Eder K., Activation of PPAR lowers synthesis and concentration of cholesterol by reduction of nuclear SREBP-2 Biochemical Pharmacology 2007 73 4 574 585
102. Qin X., Xie X., Fan Y., Peroxisome proliferator-activated receptor- induces insulin-induced gene-1 and suppresses hepatic lipogenesis in obese diabetic mice Hepatology 2008 48 2 432 441
103. Davies J. P., Levy B., Ioannou Y. A., Evidence for a niemann-pick C (NPC) gene family: identification and characterization of NPC1L1 Genomics 2000 65 2 137 145
104. Altmann S. W., Davis H. R. Jr., Zhu L.-J., Niemann-pick C1 like 1 protein is critical for intestinal cholesterol absorption Science 2004 303 5661 1201 1204
105. Berge K. E., Tian H., Graf G. A., Accumulation of dietary cholesterol in sitosterolemia caused by mutations in adjacent ABC transporters Science 2000 290 5497 1771 1775
106. Yu L., Li-Hawkins J., Hammer R. E., Overexpression of ABCG5 and ABCG8 promotes biliary cholesterol secretion and reduces fractional absorption of dietary cholesterol Journal of Clinical Investigation 2002 110 5 671 680
107. Umeda Y., Kako Y., Mizutani K., Inhibitory action of gemfibrozil on cholesterol absorption in rat intestine Journal of Lipid Research 2001 42 8 1214 1219
108. van der Veen J. N., Kruit J. K., Havinga R., Reduced cholesterol absorption upon PPAR activation coincides with decreased intestinal expression of NPC1L1 Journal of Lipid Research 2005 46 3 526 534
109. Valasek M. A., Clarke S. L., Repa J. J., Fenofibrate reduces intestinal cholesterol absorption via PPAR -dependent modulation of NPC1L1 expression in mouse Journal of Lipid Research 2007 48 12 2725 2735
110. Kok T., Wolters H., Bloks V. W., Induction of hepatic ABC transporter expression is part of the PPAR -mediated fasting response in the mouse Gastroenterology 2003 124 1 160 171
111. Janowski B. A., Grogan M. J., Jones S. A., Structural requirements of ligands for the oxysterol liver X receptors LXR and LXR Proceedings of the National Academy of Sciences of the United States of America 1999 96 1 266 271
112. Fu X., Menke J. G., Chen Y., 27-hydroxycholesterol is an endogenous ligand for liver X receptor in cholesterol-loaded cells Journal of Biological Chemistry 2001 276 42 38378 38387
113. Lehmann J. M., Kliewer S. A., Moore L. B., Activation of the nuclear receptor LXR by oxysterols defines a new hormone response pathway Journal of Biological Chemistry 1997 272 6 3137 3140
114. Repa J. J., Berge K. E., Pomajzl C., Richardson J. A., Hobbs H., Mangelsdorf D. J., Regulation of ATP-binding cassette sterol transporters ABCG5 and ABCG8 by the liver X receptors α and β Journal of Biological Chemistry 2002 277 21 18793 18800
115. Kennedy M. A., Venkateswaran A., Tarr P. T., Characterization of the human ABCG1 gene. Liver X receptor activates an internal promoter that produces a novel transcript encoding an alternative form of the protein Journal of Biological Chemistry 2001 276 42 39438 39447 (Pubitemid 37371322)
116. Peet D. J., Turley S. D., Ma W., Cholesterol and bile acid metabolism are impaired in mice lacking the nuclear oxysterol receptor LXRα Cell 1998 93 5 693 704
117. Joseph S. B., McKilligin E., Pei L., Synthetic LXR ligand inhibits the development of atherosclerosis in mice Proceedings of the National Academy of Sciences of the United States of America 2002 99 11 7604 7609
118. Tangirala R. K., Bischoff E. D., Joseph S. B., Identification of macrophage liver X receptors as inhibitors of atherosclerosis Proceedings of the National Academy of Sciences of the United States of America 2002 99 18 11896 11901
119. Schultz J. R., Tu H., Luk A., Role of LXRs in control of lipogenesis Genes and Development 2000 14 22 2831 2838
120. Goodwin B. J., Zuercher W. J., Collins J. L., Recent advances in liver X receptor biology and chemistry Current Topics in Medicinal Chemistry 2008 8 9 781 791
121. Yoshikawa T., Shimano H., Amemiya-Kudo M., Identification of liver X receptor-retinoid X receptor as an activator of the sterol regulatory element-binding protein 1c gene promoter Molecular and Cellular Biology 2001 21 9 2991 3000
122. Repa J. J., Liang G., Ou J., Regulation of mouse sterol regulatory element-binding protein-1c gene (SREBP-1c) by oxysterol receptors, LXR and LXR Genes and Development 2000 14 22 2819 2830
123. Miyata K. S., McCaw S. E., Patel H. V., Rachubinski R. A., Capone J. P., The orphan nuclear hormone receptor LXR interacts with the peroxisome proliferator-activated receptor and inhibits peroxisome proliferator signaling Journal of Biological Chemistry 1996 271 16 9189 9192
124. Ide T., Shimano H., Yoshikawa T., Cross-talk between peroxisome proliferator-activated receptor (PPAR) and liver X receptor (LXR) in nutritional regulation of fatty acid metabolismII: LXRs suppress lipid degradation gene promoters through inhibition of PPAR signaling Molecular Endocrinology 2003 17 7 1255 1267 (Pubitemid 36819949)
125. Inoue J., Satoh S., Kita M., PPAR gene expression is up-regulated by LXR and PXR activators in the small intestine Biochemical and Biophysical Research Communications 2008 371 4 675 678
126. Colin S., Bourguignon E., Boullay A.-B., Intestine-specific regulation of PPAR gene transcription by liver X receptors Endocrinology 2008 149 10 5128 5135
127. Yahagi N., Shimano H., Hasty A. H., A crucial role of sterol regulatory element-binding protein-1 in the regulation of lipogenic gene expression by polyunsaturated fatty acids Journal of Biological Chemistry 1999 274 50 35840 35844
128. Xu J., Nakamura M. T., Cho H. P., Clarke S. D., Sterol regulatory element binding protein-1 expression is suppressed by dietary polyunsaturated fatty acids. A mechanism for the coordinate suppression of lipogenic genes by polyunsaturated fats Journal of Biological Chemistry 1999 274 33 23577 23583
129. Yoshikawa T., Shimano H., Yahagi N., Polyunsaturated fatty acids suppress sterol regulatory element-binding protein 1c promoter activity by inhibition of liver X receptor (LXR) binding to LXR response elements Journal of Biological Chemistry 2002 277 3 1705 1711
130. Matsusue K., Miyoshi A., Yamano S., Gonzalez F. J., Ligand-activated PPAR efficiently represses the induction of LXR-dependent promoter activity through competition with RXR Molecular and Cellular Endocrinology 2006 256 1-2 23 33
131. Li A. C., Binder C. J., Gutierrez A., Differential inhibition of macrophage foam-cell formation and atherosclerosis in mice by PPAR, /, and Journal of Clinical Investigation 2004 114 11 1564 1576
132. Claudel T., Leibowitz M. D., Fivet C., Reduction of atherosclerosis in apolipoprotein E knockout mice by activation of the retinoid X receptor Proceedings of the National Academy of Sciences of the United States of America 2001 98 5 2610 2615
133. Duezt H., Chao Y.-S., Hernandez M., Reduction of atherosclerosis by the peroxisome proliferator-activated receptor agonist fenofibrate in mice Journal of Biological Chemistry 2002 277 50 48051 48057
134. Tordjman K., Bernal-Mizrachi C., Zemany L., PPAR deficiency reduces insulin resistance and atherosclerosis in apoE-null mice Journal of Clinical Investigation 2001 107 8 1025 1034
135. Fu T., Kashireddy P., Borensztajn J., The peroxisome-proliferator- activated receptor agonist ciprofibrate severely aggravates hypercholesterolaemia and accelerates the development of atherosclerosis in mice lacking apolipoprotein E Biochemical Journal 2003 373 3 941 947
136. Torra I. P., Claudel T., Duval C., Kosykh V., Fruchart J.-C., Staels B., Bile acids induce the expression of the human peroxisome proliferator-activated receptor gene via activation of the farnesoid X receptor Molecular Endocrinology 2003 17 2 259 272
137. Watanabe M., Houten S. M., Wang L., Bile acids lower triglyceride levels via a pathway involving FXR, SHP, and SREBP-1c Journal of Clinical Investigation 2004 113 10 1408 1418
138. Sinal C. J., Yoon M., Gonzalez F. J., Antagonism of the actions of peroxisome proliferator-activated receptor- by Bile Acids Journal of Biological Chemistry 2001 276 50 47154 47162
139. Kassam A., Capone J. P., Rachubinski R. A., The short heterodimer partner receptor differentially modulates peroxisome proliferator-activated receptor -mediated transcription from the peroxisome proliferator-response elements of the genes encoding the peroxisomal -oxidation enzymes acyl-CoA oxidase and hydratase-dehydrogenase Molecular and Cellular Endocrinology 2001 176 1-2 49 56
140. Nishizawa H., Yamagata K., Shimomura I., Small heterodimer partner, an orphan nuclear receptor, augments peroxisome proliferator-activated receptor transactivation Journal of Biological Chemistry 2002 277 2 1586 1592
141. George J., Liddle C., Nonalcoholic fatty liver disease: pathogenesis and potential for nuclear receptors as therapeutic targets Molecular Pharmaceutics 2008 5 1 49 59
142. Kallwitz E. R., McLachlan A., Cotler S. J., Role of peroxisome proliferators-activated receptors in the pathogenesis and treatment of nonalcoholic fatty liver disease World Journal of Gastroenterology 2008 14 1 22 28
143. Galli A., Crabb D., Price D., Peroxisome proliferator-activated receptor transcriptional regulation is involved in platelet-derived growth factor-induced proliferation of human hepatic stellate cells Hepatology 2000 31 1 101 108
144. Galli A., Crabb D. W., Ceni E., Antidiabetic thiazolidinediones inhibit collagen synthesis and hepatic stellate cell activation in vivo and in vitro Gastroenterology 2002 122 7 1924 1940
145. Miyahara T., Schrum L., Rippe R., Peroxisome proliferator-activated receptors and hepatic stellate cell activation Journal of Biological Chemistry 2000 275 46 35715 35722
146. Senekeo-Effenberger K., Chen S., Brace-Sinnokrak E., Expression of the human UGT1 locus in transgenic mice by 4-chloro-6-(2,3-xylidino)-2- pyrimidinylthioacetic acid (WY-14643) and implications on drug metabolism through peroxisome proliferator-activated receptor activation Drug Metabolism and Disposition 2007 35 3 419 427
147. Marra F., DeFranco R., Robino G., Thiazolidinedione treatment inhibits bile duct proliferation and fibrosis in a rat model of chronic cholestasis World Journal of Gastroenterology 2005 11 32 4931 4938
148. Cindoruk M., Kerem M., Karakan T., Peroxisome proliferators-activated alpha agonist treatment ameliorates hepatic damage in rats with obstructive jaundice: an experimental study BMC Gastroenterology 2007 7, article 44
149. Barbier O., Trottier J., Kaeding J., Caron P., Verreault M., Lipid-activated transcription factors control bile acid glucuronidation Molecular and Cellular Biochemistry 2009 1 6